Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy

Prostate International ◽

10.1016/j.prnil.2015.10.015 ◽

2015 ◽

Vol 3 (4) ◽

pp. 123-126 ◽

Author(s):

Minyong Kang ◽

Sangchul Lee ◽

Jong Jin Oh ◽

Sung Kyu Hong ◽

Sang Eun Lee ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Systemic Chemotherapy ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network

European Journal of Cancer ◽

10.1016/j.ejca.2021.06.034 ◽

2021 ◽

Vol 155 ◽

pp. 127-135

Author(s):

Susanna Bianchi ◽

Alessandra Mosca ◽

Alberto Dalla Volta ◽

Veronica Prati ◽

Cinzia Ortega ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Phase Iii ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Phase Iii Study

Download Full-text

MP53-06 THE EFFECTIVE PERIOD OF FIRST ANDROGEN DEPRIVATION THERAPY BECOMES AN PROGNOSTIC THE EFFECTIVE PERIOD OF FIRST ANDROGEN-DEPRIVATION THERAPY BECOMES AN PROGNOSTIC FACTOR IN DOCETAXEL CHEMOTHERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER PATIENTS

The Journal of Urology ◽

10.1016/j.juro.2017.02.1657 ◽

2017 ◽

Vol 197 (4S) ◽

Author(s):

Keisuke Shigeta ◽

Takeo Kosaka ◽

Ryuichi MIzuno ◽

Toshiaki Shinojima ◽

Eiji KIkuchi ◽

...

Keyword(s):

Prostate Cancer ◽

Prognostic Factor ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Effective Period ◽

Castration Resistant ◽

Docetaxel Chemotherapy

Download Full-text

619P Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network

Annals of Oncology ◽

10.1016/j.annonc.2020.08.878 ◽

2020 ◽

Vol 31 ◽

pp. S512

Author(s):

A. Berruti ◽

A. Mosca ◽

S. Bianchi ◽

V. Prati ◽

C. Ortega ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Phase Iii ◽

Castration Resistant Prostate Cancer ◽

Intermittent Schedule ◽

Castration Resistant ◽

Phase Iii Study

Download Full-text

Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

International Journal of Clinical Oncology ◽

10.1007/s10147-019-01395-0 ◽

2019 ◽

Vol 24 (5) ◽

pp. 554-556

Author(s):

Keisuke Shigeta ◽

Takeo Kosaka ◽

Hiroshi Hongo ◽

Yoshinori Yanai ◽

Kazuhiro Matsumoto ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Clinical Benefit ◽

Poor Response ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive diseae? Mature analysis of the GETUG-AFU 15 phase III trial

Annals of Oncology ◽

10.1093/annonc/mdw372.45 ◽

2016 ◽

Vol 27 ◽

pp. vi259 ◽

Author(s):

P. Lavaud ◽

G. Gravis ◽

C. Legoupil ◽

S. Foulon ◽

F. Joly ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Phase Iii ◽

Castration Resistant Prostate Cancer ◽

Phase Iii Trial ◽

Castration Resistant ◽

Hormone Sensitive ◽

Mature Analysis

Download Full-text

Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

International Journal of Clinical Oncology ◽

10.1007/s10147-018-01388-5 ◽

2019 ◽

Vol 24 (5) ◽

pp. 546-553 ◽

Author(s):

Keisuke Shigeta ◽

Takeo Kosaka ◽

Hiroshi Hongo ◽

Yoshinori Yanai ◽

Kazuhiro Matsumoto ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Clinical Benefit ◽

Poor Response ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

PLoS ONE ◽

10.1371/journal.pone.0229754 ◽

2020 ◽

Vol 15 (3) ◽

pp. e0229754

Author(s):

Zongwei Wang ◽

Tuo Deng ◽

Xingbo Long ◽

Xueming Lin ◽

Shulin Wu ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Advanced age and early androgen deprivation therapy increase survival at different stages of the treatment in castration resistant prostate cancer patients

European Urology Open Science ◽

10.1016/s2666-1683(21)03147-5 ◽

2021 ◽

Vol 33 ◽

pp. S296

Author(s):

A.V. Ojeda Claro ◽

C.M. Fernández-Ávila ◽

M.F. Lorenzo Gómez ◽

M.J. Ledo Cepero ◽

E. Ruíz Guerrero ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Advanced Age ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach

Asian Journal of Urology ◽

10.1016/j.ajur.2015.10.003 ◽

2016 ◽

Vol 3 (1) ◽

pp. 33-38 ◽

Author(s):

Kazuhiro Nagao ◽

Hideyasu Matsuyama ◽

Masahiro Nozawa ◽

Isao Hara ◽

Tsukasa Nishioka ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Metastatic Prostate Cancer ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Propensity Scoring ◽

Castration Resistant

Download Full-text

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Therapeutic Advances in Medical Oncology ◽

10.1177/1758835920978134 ◽

2020 ◽

Vol 12 ◽

pp. 175883592097813

Author(s):

Pernelle Lavaud ◽

Clément Dumont ◽

Constance Thibault ◽

Laurence Albiges ◽

Giulia Baciarello ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Androgen Receptor ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Next Generation ◽

Castration Resistant Prostate Cancer ◽

Free Survival ◽

Castration Resistant ◽

Recent Advances

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

Download Full-text